AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38475757 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol prohibited in cigarettes only (non-menthol cigarette and menthol flavored e-cigarette)
Number of subjects: 150
Study 38475757 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol prohibited in both cigarettes and e-cigarettes (non-menthol cigarette and tobacco flavored e-cigarette)
Number of subjects: 150
Study 38475758 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pre-consult patient decision aid
Number of subjects: 204
Study 38475758 — intervention group
Group type: COMPARATOR
Intervention: Paper-based in-consult patient decision aid
Number of subjects: 204
Study 38475764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular gold micro-particles with hyaluronic acid (20 mg, 72,000 particles, 20-40 μm in diameter)
Number of subjects: 136
Study 38475764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular gold micro-particles with hyaluronic acid
Number of subjects: 136
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative Stereotactic Radiosurgery (SRS)
Number of subjects: 0
Study 38475765 — intervention group
Group type: COMPARATOR
Intervention: Post-operative Stereotactic Radiosurgery (SRS)
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Survival
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of planned therapies
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to systemic therapy
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to regional progression
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to CNS progression
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to subsequent treatment
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of radiation necrosis
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of local recurrence
Number of subjects: 0
Study 38475765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of leptomeningeal disease
Number of subjects: 0
Study 38475768 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sessions of behavioral parent training with optional booster sessions
Number of subjects: 0
Study 38475768 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 38475786 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (human interleukin 1 receptor antagonist)
Number of subjects: 393
Study 38475786 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 393
Study 38475815 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH radiotherapy (8 Gy in a single fraction at ≥ 40 Gy/s)
Number of subjects: 10
Study 38475822 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT2) therapy
Number of subjects: 0
Study 38475822 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) vasopressor therapy
Number of subjects: 0
Study 38475923 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation of the neuroimmune modulation device (SetPoint Medical) for 1 min once per day.
Number of subjects: 60
Study 38475923 — intervention group
Group type: COMPARATOR
Intervention: Non-active (sham) stimulation for 1 min once per day.
Number of subjects: 60
Study 38476120 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (RT)
Number of subjects: 270
Study 38476120 — intervention group
Group type: COMPARATOR
Intervention: Non-radiotherapy (non-RT)
Number of subjects: 270
Study 38476213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 350
Study 38476213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 38476396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 360
Study 38476396 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 360
Study 38476466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin (34 mg, once daily)
Number of subjects: 29
Study 38476496 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 self-test kits distributed within social networks
Number of subjects: 61
Study 38476496 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving test kits from social contacts
Number of subjects: 61
Study 38476496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering self-test kits from the government
Number of subjects: 61
Study 38476496 — intervention group
Group type: COMPARATOR
Intervention: Secondary distribution of COVID-19 self-test kits
Number of subjects: 61
Study 38476746 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS, 1 mA, 20 min)
Number of subjects: 123
Study 38476746 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation (control)
Number of subjects: 123
Study 38476961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichoptic therapy with eye-tracking, 1.5 hours, 6 days per week for 1 month
Number of subjects: 1
Study 38476961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichoptic therapy with eye-tracking, continued for 4 months
Number of subjects: 1
Study 38477110 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 34
Study 38477162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639
Study 38477162 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study 38477412 — intervention group
Group type: EXPERIMENTAL
Intervention: Buss-Perry Aggression Questionnaire-short form (BPAQ-SF)
Number of subjects: 0
Study 38477494 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal permanent mesh
Number of subjects: 7846
Study 38477494 — intervention group
Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 7846
Study 38477675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose Morphine
Number of subjects: 0
Study 38477704 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive central systolic blood pressure (invCSBP) measurement
Number of subjects: 168
Study 38477704 — intervention group
Group type: COMPARATOR
Intervention: Cuff-based brachial systolic blood pressure (cuffSBP) measurement
Number of subjects: 168
Study 38477706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spots (DBS) sampling for metronidazole concentrations
Number of subjects: 143
Study 38477706 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized population pharmacokinetic model of metronidazole
Number of subjects: 143
Study 38477706 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour dosing interval for metronidazole
Number of subjects: 143
Study 38477913 — intervention group
Group type: EXPERIMENTAL
Intervention: QCA-guided PCI
Number of subjects: 1528
Study 38477913 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 1528
Study 38477966 — intervention group
Group type: EXPERIMENTAL
Intervention: CARv3-TEAM-E T cells
Number of subjects: 3
Study 38477975 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote RC2S (Cognitive remediation of social cognition in Schizophrenia) for 24 biweekly individual 1-hour sessions with a therapist.
Number of subjects: 20
Study 38477985 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA blood-based test
Number of subjects: 7861
Study 38477987 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan monotherapy
Number of subjects: 93
Study 38477987 — intervention group
Group type: COMPARATOR
Intervention: Anti-C5 therapy
Number of subjects: 93
Study 38477988 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3-Mat vaccine
Number of subjects: 5328
Study 38477988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5328
Study 38477986 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation multitarget stool DNA test
Number of subjects: 20176
Study 38477986 — intervention group
Group type: COMPARATOR
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 20176
Study 38478023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 189
Study 38478042 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) dosages ranging from 0-1.6 mg combined with 10 mg enalapril maleate, taken daily for 8 weeks
Number of subjects: 2697
Study 38478255 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient parenteral antimicrobial therapy (OPAT) with anti-infective medications administered at home using elastomeric pumps for a median duration of 15 days.
Number of subjects: 77
Study 38478366 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (150 to 300 mg twice a day)
Number of subjects: 43
Study 38478366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 38478488 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintain serum potassium ≥ 3.6 mEq/L
Number of subjects: 1684
Study 38478488 — intervention group
Group type: COMPARATOR
Intervention: Maintain serum potassium ≥ 4.5 mEq/L
Number of subjects: 1684
Study 38478535 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis through low-pass whole genome sequencing and whole exome sequencing.
Number of subjects: 3734
Study 38478535 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) built through a hybrid approach including effect size of each SNP, number of effect alleles observed, sample ploidy, total number of SNPs included in the PRS, and number of non-missing SNPs in the sample.
Number of subjects: 3734
Study 38478535 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for pathogenic or likely pathogenic variants in 8 genes (ABCG5, ABCG8, APOB, APOE, LDLR, LDLRAP1, LIPA, PCSK9).
Number of subjects: 3734
Study 38478535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis.
Number of subjects: 3734
Study 38478634 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV-NG2 + HRIG
Number of subjects: 640
Study 38478634 — intervention group
Group type: COMPARATOR
Intervention: PVRV + HRIG
Number of subjects: 640
Study 38478634 — intervention group
Group type: COMPARATOR
Intervention: HDCV + HRIG
Number of subjects: 640
Study 38478634 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV-NG2 alone
Number of subjects: 640
Study 38478705 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1647 (30, 90, 180, or 300 µg)
Number of subjects: 154
Study 38478705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 38479114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 6-day program of exercise, self-management workshops, and spa therapy
Number of subjects: 150
Study 38479114 — intervention group
Group type: COMPARATOR
Intervention: Self-management alone (control group)
Number of subjects: 150
Study 38479118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunlametinib
Number of subjects: 100
Study 38479192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine infusions (3 during acute phase, 4 additional if remitted)
Number of subjects: 74
Study 38479192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine infusions
Number of subjects: 74
Study 38479195 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 148
Study 38479344 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation exercise program with teleconsultations with a specialist nurse for 4 weeks.
Number of subjects: 79
Study 38479344 — intervention group
Group type: COMPARATOR
Intervention: Control group participated in physical activity howsoever they wished.
Number of subjects: 79
Study 38479748 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC with directly observed treatment (DOT) for the full course in under 5-year-old children
Number of subjects: 62
Study 38479748 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC with directly observed treatment (DOT) for the full course in under 10-year-old children
Number of subjects: 62
Study 38479748 — intervention group
Group type: COMPARATOR
Intervention: SMC without directly observed treatment (DOT) for the full course in under 5-year-old children
Number of subjects: 62
Study 38479746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Prevention Pill (DPP)
Number of subjects: 126
Study 38479746 — intervention group
Group type: COMPARATOR
Intervention: Oral Pre-Exposure Prophylaxis (PrEP)
Number of subjects: 126
Study 38479746 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraception (OC)
Number of subjects: 126
Study 38479751 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0
Study 38479751 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 0
Study 38479751 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 38479751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38479794 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulus at the site of skin puncture beginning 10 seconds prior to a heel stick
Number of subjects: 134
Study 38479794 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control)
Number of subjects: 134
Study 38479803 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cytoreductive surgery
Number of subjects: 5000
Study 38479803 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by interval cytoreductive surgery
Number of subjects: 5000
Study 38479820 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hsCRP values
Number of subjects: 1047
Study 38479939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish hydrolysate supplementation for 4 weeks
Number of subjects: 0
Study 38479939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38479953 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast volume reduction (CVR) group using the DyeVert CM diversion system (n=276)
Number of subjects: 550
Study 38479953 — intervention group
Group type: COMPARATOR
Intervention: Control group using a conventional manual or automatic injection syringe (n=274)
Number of subjects: 550
Study 38479953 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast volume reduction (CVR) group
Number of subjects: 550
Study 38479953 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 550
Study 38480098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual vein embolization (DVE)
Number of subjects: 10
Study 38480590 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-based personalized antiplatelet therapy; specific dosage and duration not mentioned.
Number of subjects: 0
Study 38480590 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet therapy without genotype information; specific details not mentioned.
Number of subjects: 0
Study 38480624 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care (specific intervention details not provided)
Number of subjects: 573
Study 38480632 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 500 mL fluid bolus
Number of subjects: 40
Study 38480632 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 40
Study 38480922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2
Number of subjects: 6
Study 38481024 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention intervention in SR-settings
Number of subjects: 24
Study 38481024 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 24
Study 38481111 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 38481111 — intervention group
Group type: COMPARATOR
Intervention: Active Surveillance
Number of subjects: 0
Study 38481147 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based surveillance and respiratory specimen collection kits; participants monitored weekly for respiratory illness symptoms and collected specimens at symptom onset.
Number of subjects: 1371
Study 38481147 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based surveillance and remote contact tracing; longitudinal specimen collection every 2 days for 14 days.
Number of subjects: 1371
Study 38481166 — intervention group
Group type: EXPERIMENTAL
Intervention: National Basic Public Health Service Program (NBPHSP) policy
Number of subjects: 197
Study 38481166 — intervention group
Group type: EXPERIMENTAL
Intervention: PHC providers' capacity and income level
Number of subjects: 197
Study 38481166 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' engagement in care
Number of subjects: 197
Study 38481166 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health approaches
Number of subjects: 197
Study 38481195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer navigation intervention
Number of subjects: 113
Study 38481195 — intervention group
Group type: COMPARATOR
Intervention: Lifetime physical violence
Number of subjects: 113
Study 38481195 — intervention group
Group type: COMPARATOR
Intervention: Lifetime sexual violence
Number of subjects: 113
Study 38481208 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on glucagon secretion
Number of subjects: 24
Study 38481208 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on GLP-1 secretion
Number of subjects: 24
Study 38481208 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on GIP secretion
Number of subjects: 24
Study 38481208 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on C-peptide secretion
Number of subjects: 24
Study 38481208 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm effects on glucose levels
Number of subjects: 24
Study 38481209 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus 2 mg once a day for a maximum of 60 months
Number of subjects: 15
Study 38481211 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedures via blood clot
Number of subjects: 18
Study 38481293 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive interactive training program (VICT)
Number of subjects: 32
Study 38481293 — intervention group
Group type: COMPARATOR
Intervention: Comparable VR game without executive function training
Number of subjects: 32
Study 38481318 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapies (specific type not detailed)
Number of subjects: 73
Study 38481504 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma oxalate (POx) levels
Number of subjects: 45
Study 38481504 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary oxalate (UOx) levels
Number of subjects: 45
Study 38481504 — intervention group
Group type: COMPARATOR
Intervention: High POx levels (HPO) vs Normal POx levels (NPO)
Number of subjects: 45
Study 38481666 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate (LHRH agonist)
Number of subjects: 592
Study 38481947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with ruxolitinib
Number of subjects: 0
Study 38482290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge strategy
Number of subjects: 0
Study 38482290 — intervention group
Group type: COMPARATOR
Intervention: Control (no nudge strategy)
Number of subjects: 0
Study 38482462 — intervention group
Group type: EXPERIMENTAL
Intervention: CM326 55 mg every two weeks (Q2W)
Number of subjects: 113
Study 38482462 — intervention group
Group type: EXPERIMENTAL
Intervention: CM326 110 mg every two weeks (Q2W)
Number of subjects: 113
Study 38482462 — intervention group
Group type: EXPERIMENTAL
Intervention: CM326 220 mg every two weeks (Q2W)
Number of subjects: 113
Study 38482462 — intervention group
Group type: EXPERIMENTAL
Intervention: CM326 220 mg every four weeks (Q4W)
Number of subjects: 113
Study 38482462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 38482528 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intervention based on pain neuroscience education and therapeutic yoga as a graded exposure to movement exercise
Number of subjects: 40
Study 38482528 — intervention group
Group type: COMPARATOR
Intervention: Usual cancer-related symptoms care (Control)
Number of subjects: 40
Study 38482816 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 43
Study 38482816 — intervention group
Group type: COMPARATOR
Intervention: Primary Arthrodesis (PA)
Number of subjects: 43
Study 38482816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ORIF and PA
Number of subjects: 43
Study 38482823 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rTMS (intermittent theta-burst stimulation to the left dorsolateral prefrontal cortex, 600 pulses/session, 8 sessions/day for 5 days)
Number of subjects: 9
Study 38482823 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rTMS
Number of subjects: 9
Study 38483145 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-week steroid stepwise reduction (SSR)
Number of subjects: 90
Study 38483145 — intervention group
Group type: COMPARATOR
Intervention: 48-week steroid stepwise reduction (SSR)
Number of subjects: 90
Study 38483145 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-week SSR
Number of subjects: 90
Study 38483145 — intervention group
Group type: COMPARATOR
Intervention: 48-week SSR
Number of subjects: 90
Study 38483248 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral vitamin D3 (VD3) for 6 weeks
Number of subjects: 101
Study 38483248 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 101
Study 38483309 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg orally once daily from days 1 to 14 every 3 weeks)
Number of subjects: 40
Study 38483366 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative neurostimulation
Number of subjects: 204
Study 38483402 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS)
Number of subjects: 1009
Study 38483412 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPORT (62.5 Gy in 25 fractions)
Number of subjects: 296